ASCO GU 2025 Bladder Cancer

Viewing 1-20 of 56 articles

ASCO GU 2025: Overcoming Challenges of Antibody Drug Conjugate Toxicity in Bladder Cancer

ASCO GU 2025: Targeting Bladder Cancer with Antibody Drug Conjugates

ASCO GU 2025: HER2 Antibody Drug Conjugate Therapy: A New Frontier in Bladder Cancer

ASCO GU 2025: Better Together? Exploring Novel Drug Combinations with Antibody Drug Conjugates

ASCO GU 2025: ResQ132A: Phase 2 Trial of Intravesical Gemcitabine Plus N-803 Versus Intravesical N-803 and BCG for Intermediate-Risk NMIBC

ASCO GU 2025: Preliminary Efficacy and Safety of Disitamab Vedotin Combined With BCG in the Treatment of High-Risk NMIBC With HER2 Expression: A Prospective, Open Label, Single-Center Study

ASCO GU 2025: Avelumab First-Line Maintenance in Patients With Advanced Urothelial Carcinoma With or Without Diabetes Mellitus: Long-Term Outcomes From JAVELIN Bladder 100

ASCO GU 2025: Nectin-4 Targeted ADC, SHR-A2102, in Patients With Advanced or Metastatic Urothelial Carcinoma: A Phase 1 Study

ASCO GU 2025: Real-World Outcomes of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

ASCO GU 2025: Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer

ASCO GU 2025: Determining an Immunohistochemical Profile to Predict Response to Intravesical Bacillus Calmette–Guérin (BCG) in Patients with High-Grade Non-Muscle Invasive Bladder Cancer.

ASCO GU 2025: Efficacy and Safety of Disitamab Vedotin plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-High Expression (2+-3+) Non-Muscle Invasive Bladder Cancer at High-Risk and Very High-Risk

ASCO GU 2025: Mental Health Monitoring in Clinical Trials for FDA-Approved Genitourinary Cancer Treatments: A Decade Review

ASCO GU 2025: Real World Toxicity Profile of Enfortumab Vedotin with or Without Pembrolizumab in Ultra Elderly Urothelial Carcinoma Patients

ASCO GU 2025: Survey-based Study of Treatment Sequencing After First Line Enfortumab Vedotin + Pembrolizumab in the Evolving Landscape of Locally Advanced or Metastatic Urothelial Cancer

ASCO GU 2025: Real-World Time on Treatment with First-Line Enfortumab Vedotin and Pembrolizumab After U.S. FDA Approval for Advanced Urothelial Cancer

ASCO GU 2025: Clinical Efficacy of Enfortumab Vedotin + Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: A Real-World Retrospective Study

ASCO GU 2025: Evolution of ctDNA Detection with Next Generation Technology

ASCO GU 2025: Clinically Advanced Urothelial Bladder Cancer in Young Onset Bladder Cancer (YOUC) Patients: A Genomic Landscape Study

ASCO GU 2025: A Phase 2 Trial of Risk Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for Muscle-Invasive Bladder Cancer (RETAIN-2)

1
2
3